Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

In the trial, the safety and efficacy of lenvatinib in combination with everolimus (arm A), or pembrolizumab (arm B), versus sunitinib (arm C) were compared as first-line treatment in patients with advanced RCC. Around 1050 patients were enrolled to the trial and they were randomised to 1 of the 3 treatment arms.

Read more in OncLive here

Share this Post!

Related post